Finance

Lists
MLYS:NASDAQ
Mineralys Therapeutics Inc
15,33 $
-1,10%
(-0,17) 1D
13 қар., 16:00:00 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MLYS...
Open
15,47 $
High
15,50 $
Low
14,78 $
Mkt. cap
1,36 млрд
Avg. vol.
1,80 млн
Volume
1,31 млн
52-wk high
45,59 $
52-wk low
14,78 $
EPS
-4,36 $
Beta
0,83
Shares outstanding
88,56 млн
No. of employees
76
Open
15,47 $
High
15,50 $
Low
14,78 $
Mkt. cap
1,36 млрд
Avg. vol.
1,80 млн
Volume
1,31 млн
52-wk high
45,59 $
52-wk low
14,78 $
EPS
-4,36 $
Beta
0,83
Shares outstanding
88,56 млн
No. of employees
76
News stories
From web sources and news partners
About Mineralys Therapeutics Inc
CEO-
Employees76
Founded2019
Headquarters-
SectorHealth Care
Industry-
Websitemineralystx.com
Analyst ratings
Based on 6 analysts giving stock ratings to MLYS in the past 3 months
Strong buy
Buy
5
Hold
1
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for MLYS in the last 3 months.
Highest
Current 15,33 $
56,00 $ (+265,30%)
Average
45,50 $ (+196,80%)
Lowest
19,00 $ (+23,94%)
Analyst
Recommendation
Action
Price target
Projected
Date
Matthew Caufield
H.C. Wainwright
Buy
Reiterated
56,00 $
+265,3%
11/10/2026
Alice Nettleton
UBS
Hold
Reiterated
19,00 $
+23,9%
11/06/2026
Mohit Bansal
Wells Fargo
Buy
Maintained
55,00 $
+258,8%
11/05/2026
Jason Gerberry
Bank of America Securities
Buy
Maintained
-
-
11/05/2026
Tara Bancroft
TD Cowen
Buy
Maintained
-
-
11/05/2026
Annabel Samimy
Stifel Nicolaus
Buy
Reiterated
52,00 $
+239,2%
11/05/2026
Unknown Analyst
UBS
Hold
Initiated
29,00 $
+89,2%
10/11/2026
Seamus Fernandez
Guggenheim
Buy
Reiterated
52,00 $
+239,2%
08/12/2026
Richard Law CFA
Goldman Sachs
Buy
Maintained
40,00 $
+160,9%
08/12/2026
Unknown Analyst
Wells Fargo
Buy
Maintained
55,00 $
+258,8%
08/12/2026
Rami Katkhuda
LifeSci Capital
Buy
Maintained
54,00 $
+252,3%
08/12/2026
Unknown Analyst
Goldman Sachs
Buy
Reiterated
42,00 $
+174%
05/07/2026
Last report
2026 ж. 04 қар.
Fiscal period
Q3 2026
-0,64 $ / -0,55 $
-15,91%miss
Revenue / Est. (USD)
- / 0,00
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
2026 ж. қыр.
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
24,40 млн
24,36 млн
221,38 млн
22,67 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
13,88 млн
20,98 млн
24,66 млн
37,42 млн
Operating expense
38,28 млн
45,34 млн
246,04 млн
60,09 млн
Total operating expenses
38,28 млн
45,34 млн
246,04 млн
60,09 млн
Operating income
-38,28 млн
-45,34 млн
-246,04 млн
-60,09 млн
Other non operating income
1,00 мың
5,00 мың
13,00 мың
-
EBT including unusual items
-32,23 млн
-39,34 млн
-241,07 млн
-57,33 млн
EBT excluding unusual items
-32,23 млн
-39,34 млн
-241,07 млн
-57,33 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-32,23 млн
-39,34 млн
-241,07 млн
-57,33 млн
Net profit margin
-
-
-
-
Earnings per share
-0,40
-0,47
-2,85
-0,64
Interest and investment income
6,04 млн
6,00 млн
4,96 млн
5,95 млн
Interest expense
-
-
-
-3,19 млн
Net interest expenses
6,04 млн
6,00 млн
4,96 млн
2,76 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-38,27 млн
-45,33 млн
-246,04 млн
-60,08 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google қолданбалары